Group 1 - The core point of the article is that Aibo Medical (688050) has signed a letter of intent to acquire at least 51% of the shares of Demai Medical (Chongqing) Technology Co., Ltd., thereby gaining control of the company [1] - The acquisition will be financed through a combination of acquisition loans and the company's own funds [1] - Demai Medical is recognized as a leading enterprise in sports medicine in China, classified as a national high-tech enterprise and a "specialized, refined, distinctive, and innovative" small giant [1] Group 2 - Demai Medical holds 276 patented technologies and has established a modern production base and research center, demonstrating strong technological research and market competitiveness [1]

Group 1 - The company plans to acquire at least 51% of the equity of Demai Medical, with an estimated overall valuation not exceeding RMB 1 billion [1] - The initial transaction price is based on a comprehensive assessment of the target company's technological advancement, business development, and past operating performance, while also considering industry valuation levels and business synergy [1] - The final transaction price will be determined based on an evaluation report from a qualified asset appraisal agency and negotiations among the parties involved [1] Group 2 - The target company is a leading enterprise in sports medicine in China, recognized as a national high-tech enterprise and a "specialized, refined, distinctive, and innovative" small giant, holding 276 patent technologies [2] - The target company has established a modern production base and R&D center, demonstrating strong technological research and market competitiveness, and is included in the fourth batch of national high-value medical consumables procurement A group [2] - The acquisition will enhance the company's layout in the healthcare sector, leveraging synergies in R&D, manufacturing, and sales channels to improve performance and shareholder returns [2]

爱博诺德（北京）医疗科技股份有限公司 关于签订《投资意向书》的自愿披露公告 证券代码：688050 证券简称：爱博医疗 公告编号：2026-001 ● 风险提示： 1 （一）本次《投资意向书》的签署，旨在明确双方就本次交易达成的初步意 向，除"保密""尽职调查""排他期""适用法律和争议解决"条款外，所载 明的条款是非约束性的，在双方协商、批准、执行和最终签署协议之前，各方不 会因本协议条款而构成义务，具体投资事宜尚需各方共同协商确定，并以最终签 订的交易文件为准，投资意向书实施过程中尚存在不确定因素。 （二）本次《投资意向书》所涉及收购股权的交易估值为预估值，尚存在不 确定性，最终将以资产评估机构出具的评估报告结果为依据，并由交易各方结合 尽调结果等具体情况协商确定。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 爱博诺德（北京）医疗科技股份有限公司（以下简称"爱博医疗"、"公 司"或"投资方"）于 2026 年 1 月 20 日与德美联合（重庆）医疗科技有限公司 （以下简称"德美医疗"或"标的公司 ...

Group 1 - The company plans to acquire at least 51% of the equity of Demai Medical, with an estimated overall valuation not exceeding RMB 1 billion [1] - The preliminary transaction price is based on a comprehensive assessment of the target company's technological advancement, business development, and past operating performance, while also considering industry valuation levels and business synergy [1] - The final transaction price will be determined based on an evaluation report from a qualified asset appraisal agency and negotiations among the parties involved [1] Group 2 - The target company is a leading enterprise in sports medicine in China, recognized as a national high-tech enterprise and a "specialized, refined, distinctive, and innovative" small giant, holding 276 patent technologies [2] - The target company has established a modern production base and R&D center, demonstrating strong technological research and market competitiveness, and is included in the fourth batch of national high-value medical consumables procurement A group [2] - The acquisition will enhance the company's layout in the medical health sector, leveraging synergies in R&D, manufacturing, and sales channels to further improve performance and shareholder returns [2]

爱博医疗公告，公司于2026年1月20日与德美医疗及其创始人签署《投资意向书》，拟通过并购贷款及 自有资金出资方式收购德美医疗不低于51%的股权并取得其控制权。德美医疗作为国内运动医学头部企 业，拥有276项专利技术，已入选国家高值医用耗材集采A组，具备技术研发实力与市场竞争力。本次 交易不构成关联交易或重大资产重组。 ...

Core Viewpoint - The company, Aibo Medical, does not currently have products in the brain-computer interface (BCI) field and is focusing on the development and application of a full range of ophthalmic medical products for its medium to long-term development goals [2] Group 1 - The company responded to an investor inquiry regarding its technological reserves and long-term plans in the brain-computer interface area [2] - Aibo Medical's current product offerings do not include any involvement in the brain-computer interface sector [2] - The company's strategic and product pipeline planning will be aligned with its long-term development goals in ophthalmology [2]

Group 1 - The core viewpoint of the article is that the company, Aibo Medical, is actively advancing its overseas business and plans to enhance its global market expansion efforts [1] - The company aims to increase its international market share for relevant products as part of its internationalization strategy [1]

Core Viewpoint - The company is accelerating its overseas market expansion through diversified initiatives and encourages investors to monitor its regular reports for specific updates on overseas business progress [2] Group 1 - The company is actively engaging with investors through interactive platforms to address inquiries [2] - The company emphasizes its commitment to diversifying its strategies for international market development [2] - Future updates regarding overseas business will be provided in the company's periodic reports [2]

Group 1 - The core viewpoint of the article is that the company, Aibo Medical, is actively investing through industrial funds to enhance its long-term development strategy and shareholder returns [1] Group 2 - The company focuses on investments that align with its industrial chain layout [1] - Aibo Medical emphasizes multiple measures to increase value for shareholders [1]

Core Viewpoint - The company is exploring the integration of AI technology with its core business, particularly in the fields of myopia prevention and vision care, despite its artificial lens products not currently involving AI applications [1] Group 1: AI Integration - The company has implemented the Puno Tong AI digital fitting system in the myopia prevention sector [1] - In the vision care sector, the company collaborates with partners to integrate embodied intelligent robot technology into health retail scenarios, creating a 24-hour smart store for contact lenses [1] - These applications provide technological support for the company's product production and services [1] Group 2: Ongoing Exploration - The company continues to monitor cutting-edge developments in the integration of AI and medical devices [1] - It aims to explore directions for intelligent upgrades based on its actual situation [1]